The treatment of T cells with the bromodomain and extra-terminal motif (BET) bromodomain inhibitor downregulating c-Myc-dependent target genes [132] resulted in the enhanced expansion of CD8+ TSCM cells and TCM cells, improved the persistence and anti-tumor activity of CART cells in an ALL model [133]. The gene discussed is CD8A; the disease is neoplasm.